OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 122 filers reported holding OCULAR THERAPEUTIX INC in Q2 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $233,619 | -10.8% | 74,401 | +46.6% | 0.00% | – |
| Q2 2023 | $261,942 | +236.9% | 50,764 | +244.0% | 0.00% | – |
| Q1 2023 | $77,759 | +112.0% | 14,755 | +13.0% | 0.00% | – |
| Q4 2022 | $36,685 | -74.7% | 13,055 | -62.6% | 0.00% | – |
| Q3 2022 | $145,000 | +16.9% | 34,873 | +13.1% | 0.00% | – |
| Q2 2022 | $124,000 | +15.9% | 30,828 | +42.8% | 0.00% | – |
| Q1 2022 | $107,000 | -77.2% | 21,584 | -75.4% | 0.00% | -100.0% |
| Q4 2021 | $470,000 | +98.3% | 87,602 | +269.2% | 0.00% | – |
| Q3 2021 | $237,000 | -34.7% | 23,729 | -7.3% | 0.00% | -100.0% |
| Q2 2021 | $363,000 | -15.0% | 25,593 | -1.6% | 0.00% | 0.0% |
| Q1 2021 | $427,000 | -17.1% | 25,999 | +4.5% | 0.00% | 0.0% |
| Q4 2020 | $515,000 | +221.9% | 24,890 | +18.4% | 0.00% | – |
| Q3 2020 | $160,000 | -61.3% | 21,014 | -57.6% | 0.00% | -100.0% |
| Q2 2020 | $413,000 | +436.4% | 49,619 | +220.6% | 0.00% | – |
| Q1 2020 | $77,000 | – | 15,476 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 6,122,089 | $19,223 | 100.00% |
| Opaleye Management Inc. | 6,468,000 | $20,309,520 | 6.61% |
| DELTEC ASSET MANAGEMENT LLC | 2,061,797 | $6,474,043 | 1.48% |
| Endurant Capital Management LP | 353,707 | $1,110,640 | 1.00% |
| SECTORAL ASSET MANAGEMENT INC | 969,350 | $3,043,759 | 0.59% |
| NOTTINGHAM ADVISORS, INC. | 194,266 | $609,995 | 0.09% |
| Covestor Ltd | 37,404 | $117 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 233,582 | $733 | 0.06% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 342,111 | $1,074,229 | 0.03% |
| Polar Asset Management Partners Inc. | 263,763 | $828,216 | 0.02% |